41 – 60 of 83
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations
(
- Contribution to journal › Article
-
Mark
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
(
- Contribution to journal › Article
-
Mark
Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels : Results from the EPIC cohort
(
- Contribution to journal › Article
-
Mark
Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication
(
- Contribution to journal › Article
-
Mark
Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study
(
- Contribution to journal › Article
-
Mark
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as Primary Treatment of Ovarian Cancer : A Review of the Current Literature
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation
(
- Contribution to journal › Article
-
Mark
Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker
(
- Contribution to journal › Article
-
Mark
Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models : results from the EPIC cohort
(
- Contribution to journal › Article
-
Mark
Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG)
(
- Contribution to journal › Article
- 2016
-
Mark
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
(
- Contribution to journal › Article
- 2015
-
Mark
Intrinsic subtypes and prognostic implications in epithelial ovarian cancer
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing
(
- Contribution to journal › Article
-
Mark
Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort
(
- Contribution to journal › Article
-
Mark
Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort
(
- Contribution to journal › Article
- 2014
-
Mark
Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer
(
- Contribution to journal › Article
- 2013
-
Mark
Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer
(
- Contribution to journal › Article
-
Mark
Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study.
(
- Contribution to journal › Article
- 2012
-
Mark
Cancer predisposing BARD1 mutations in breast-ovarian cancer families
(
- Contribution to journal › Article
-
Mark
Discovery of Dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer
(
- Contribution to journal › Article